CAMBRIDGE, Mass., September 8, 2021 – MOMA Therapeutics, a biopharmaceutical company discovering the next generation of precision medicines by targeting molecular machines that underlie human disease, today announced that Semi Trotto has been appointed as the company’s chief people and experience officer. In this newly created role, Ms. Trotto will be responsible for helping develop MOMA’s people, shaping company culture, and managing internal and external communications, facilities and administration.
“Semi is a seasoned executive with deep experience in company buildout during the growth phase of biotechs, exactly where we find ourselves at the moment,” said Asit Parikh, M.D., Ph.D., president and CEO of MOMA. “She is widely regarded as a consummate professional who delivers for her team through pragmatic and lasting solutions. As MOMA grows, we continue to maintain a strong emphasis on the development of our people, and I am thrilled to have a partner like Semi on board to lead our team.”
Ms. Trotto brings to MOMA more than 20 years of experience in human resources, with a focus on talent acquisition and management, leading change and transformation, and individual and team coaching and development. Prior to MOMA, Ms. Trotto was at Thrive Earlier Detection, where she initially served as chief people officer since the company’s inception. In 2021, she was appointed to general manager following Thrive’s acquisition by Exact Sciences. Previously, Ms. Trotto held roles as vice president and head of human resources at Editas Medicine and vice president of human resources for oncology at Baxalta until its acquisition by Shire. Earlier in her career, Semi spent 11 years at Bristol-Myers Squibb, where she held roles of increasing responsibility across the company’s R&D and commercial enterprises. Ms. Trotto holds a B.S. in industrial management and economics from Carnegie-Mellon University and an MBA from Cornell University.
“MOMA is a truly special company that holds tremendous potential to make a meaningful difference for patients through an entirely new scientific approach. Equally unique are the people who make up MOMA’s DNA — relentless drug hunters who represent some of the brightest minds in our industry,” said Ms. Trotto. “I am excited and honored to join MOMA at this important inflection point to lend my experience in defining the company’s vibrant culture and growth of the team.”
About MOMA Therapeutics
MOMA Therapeutics is committed to discovering the next generation of precision medicines by targeting molecular machines that underlie human disease. Bringing together seminal scientific advancements in biochemistry, biophysics, structural biology, chemistry and functional genomics, the company is establishing a platform to exploit a key vulnerability inherent to all enzymes in the class: their dependence on well-coordinated, stepwise changes in protein conformation. By focusing this platform on disease-causing targets, MOMA aims to develop high impact, precision medicines for patients with unmet medical needs. MOMA Therapeutics is a private company launched in 2020 and is financed by world-class biotech investors, including Third Rock Ventures, Nextech Invest, Cormorant Asset Management, Creacion Ventures, Casdin Capital, Alexandria Venture Investments and Rock Springs Capital.
Katie Engleman, 1AB